<DOC>
	<DOC>NCT00216723</DOC>
	<brief_summary>This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.</brief_summary>
	<brief_title>Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder</brief_title>
	<detailed_description>This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder. Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physician's assessment. Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physician's assessment. This study will be continued for 6 years. The final report of Aripiprazole PMS will be submitted to KFDA on December 28, 2009.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to DSMIV criteria Age: more than 18 years of age Unqualified patients judged by study investigator(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Aripiprazole</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar Disorder</keyword>
</DOC>